Sign in
Taking people in United StatesPhase 2

Cannabidiol and Alcohol Use Disorder Phenotypes

Key facts

Who runs it
University of Colorado, Denver
Where
Aurora, United StatesSee the site
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
150 people, planned
Started
21 Apr 2026
Expected to end
31 Aug 2029
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Full-Spectrum Cannabidiol (CBD)
  • Broad-Spectrum Cannabidiol (CBD)
  • Placebo
Record updated
16 September 2026

Who can take part

Age
21 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (9)Hide the full registry criteria

Who can take part

  • Age 21-65
  • Have used CBD and cannabis at least once in the last year
  • Regularly drink alcohol
  • Able to provide informed consent and attend in-person study visits

Who cannot take part

  • Current use of medications known to have major interaction with Epidiolex, Marinol, or alcohol
  • Current use of antiepileptic medication or any psychotropic medication besides antidepressants
  • Medical conditions that contraindicates the use of CBD or alcohol
  • Current medical conditions that may require intensive care during the study period; Not everyone will qualify to be in the study. Other inclusion and exclusion criteria will be evaluated by the study team
  • Pregnant, nursing, or planning a pregnancy

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Alcohol use disorder

This trial is currently available in United States.

  • University of Colorado School of Medicine. Anschutz Medical CampusAurora, United StatesContact: Hollis C Karoly, PhDTaking people

About the trial

What the trial wants to find out

The goal of this study is to learn how CBD affects drinking in people who drink alcohol regularly. Researchers want to see if CBD can help people drink less and reduce problems related to alcohol use.

The 3 groups in the trial

  • Full-Spectrum CBDTreatment being tested

    Subjects will take 200 mg of full-spectrum CBD (\[fsCBD\] CBD that contains \<0.3% THC) daily for 8 weeks. The total dose is split into a morning and evening dose, such that participants in the fsCBD condition will take approximately 100mg fsCBD in the morning (2 capsules) and 100mg fsCBD in the evening (2 capsules).

    Treatment: Full-Spectrum Cannabidiol (CBD)

  • Broad- Spectrum CBDTreatment being tested

    Subjects will take 200 mg of broad-spectrum CBD (\[bsCBD\] CBD that contains no THC) daily for 8 weeks. The total dose is split into a morning and evening dose, such that participants in the bsCBD condition will take approximately 100mg bsCBD in the morning (2 capsules) and 100mg bsCBD in the evening (2 capsules).

    Treatment: Broad-Spectrum Cannabidiol (CBD)

  • PlaceboPlacebo, for comparison

    Subjects will take a matching placebo solution (100% Hemp Seed Oil) daily for 8 weeks. The total dose is split into a morning and evening dose, such that participants in the condition will take approximately 100mg hemp seed oil in the morning (2 capsules) and 100mg hemp seed oil in the evening (2 capsules).

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effects of Full-spectrum Cannabidiol on Alcohol Consumption and Alcohol Use Disorder Phenotypes: Implications for Precision Medicine
Criteria questions
Built from NCT07279558, who can take part
Record updated
16 September 2026